论文部分内容阅读
目的探讨冠心病患者经皮冠状动脉介入治疗(PCI)术后支架内再狭窄与血浆诱导蛋白10(IP10)水平的相关性。方法 80例行PCI术(均植入了冠状动脉支架)治疗的冠心病患者,术后半年复查其冠状动脉(冠脉)造影并依据其再狭窄程度分组,狭窄程度在参照血管≥50%患者作为支架内再狭窄组(40例),支架内再狭窄程度<50%或者无再狭窄者作为支架内无再狭窄组(40例),同期选择冠状动脉狭窄<50%的胸痛患者40例作对照组,对比三组患者的血浆IP10水平。结果支架内再狭窄组、支架内无再狭窄组、对照组的体质量指数(BMI)、血糖、血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)的组间比较,差异均无统计学意义(P>0.05);支架内再狭窄组中的血浆IP10水平(293.5±51.5)ng/L显著高于支架内无再狭窄组(213.0±37.2)ng/L,支架内无再狭窄组患者的血浆IP10水平明显高于对照组(199.8±20.1)ng/L,差异均具有统计学意义(P<0.05)。结论冠心病患者PCI术后支架内再狭窄者和支架内无再狭窄者的血浆IP10水平差异明显,血浆IP10水平可作为评估冠心病患者PCI术后支架内再狭窄风险的独立预测指标。
Objective To investigate the relationship between in-stent restenosis and plasma-induced protein 10 (IP10) levels after percutaneous coronary intervention (PCI) in patients with coronary heart disease. Methods Eighty-eight patients with coronary heart disease underwent PCI (all of which were implanted with coronary stents). The coronary arteries (coronary angiography) were reviewed six months after surgery and grouped according to their degree of restenosis. The degree of stenosis was ≥50% As in-stent restenosis group (40 cases), the degree of in-stent restenosis <50% or no restenosis as stent restenosis group (40 cases), the same period select 40 cases of coronary artery stenosis <50% Control group, comparing plasma IP10 levels in three groups. Results There were no restenosis group in the stent restenosis group, the body mass index (BMI), blood glucose, serum total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL- (P> 0.05). The level of plasma IP10 in the in-stent restenosis group (293.5 ± 51.5) ng / L was significantly higher than that in the in-stent restenosis group (213.0 ± 37.2) ng / L. Plasma IP10 levels in patients with no restenosis within the stent group were significantly higher than those in the control group (199.8 ± 20.1) ng / L, with statistical significance (P <0.05). Conclusion There is significant difference in plasma IP10 levels between patients with coronary artery disease and those without stent restenosis after PCI. Plasma IP10 level can be used as an independent predictor for the risk of in-stent restenosis in patients with coronary artery disease.